Payment overview · 2025
General Payments
$688.29
48 reported records · 18 companies
Healthcare provider profile · identity verified
Brian A Smith, MD
Allopathic & Osteopathic Physicians|Family Medicine · VERSAILLES, KY · NPI 1992749873
Verified facts
What the public records show
CMS Open Payments records show Brian A Smith, MD received $688.29 in general payments during 2025 across 48 reported records.
ABBVIE INC. accounted for 31.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Eliquis, Jardiance, Kerendia, Rexulti, Vraylar, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VIBERZI as an associated drug or biological on 11354 records involving 5020 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Viberzi by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Vraylar by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Kerendia by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 149 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 225 claims for Eliquis by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $218.60 | 31.8% | 24 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $61.53 | 8.9% | 3 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $54.74 | 8.0% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $43.41 | 6.3% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $34.48 | 5.0% | 2 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $32.76 | 4.8% | 2 | 2025 |
| Ipsen Biopharmaceuticals, Inc | Unresolved — no canonical attribution shown | $26.47 | 3.9% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $24.62 | 3.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $22.87 | 3.3% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $21.34 | 3.1% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $20.36 | 3.0% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $20.04 | 2.9% | 1 | 2025 |
| bioMerieux Inc | Unresolved — no canonical attribution shown | $19.74 | 2.9% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $19.53 | 2.8% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $19.37 | 2.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $16.32 | 2.4% | 1 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $16.11 | 2.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.00 | 2.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $688.29 | 48 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $134.35 | 16 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $69.72 | 7 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $57.58 | 6 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $54.74 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $43.41 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $41.92 | 2 | 2025 |
Source payment records
|
|||||
| GLASSIA Normalized: glassia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $34.48 | 2 | 2025 |
Source payment records
|
|||||
| Bylvay Normalized: bylvay |
Drug | Ipsen Biopharmaceuticals, Inc | $26.47 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $24.62 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $24.28 | 1 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $22.87 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $21.34 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $20.36 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $20.04 | 1 | 2025 |
Source payment records
|
|||||
| BIOFIRE SPOTFIRE Control Station Normalized: biofire spotfire control station |
Device | bioMerieux Inc | $19.74 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $19.61 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $19.61 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $19.61 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $19.53 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $19.37 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $17.64 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $16.32 | 1 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $16.11 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $16.00 | 1 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $14.53 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 90 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 225 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 149 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
57 | 14 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VIBERZI open payments reported associated product |
CMS Open Payments — General Payments 11354 supporting records · 5020 recipient NPIs · example record 1201352948 |
Viberzi · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
149 | 52 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
71 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
132 | 23 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
90 | 90 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
225 | 55 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 1425 | 219 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 788 | 113 |
| Atorvastatin Calcium | Atorvastatin Calcium | 646 | 154 |
| Levothyroxine Sodium | Levothyroxine Sodium | 553 | 113 |
| Tramadol Hcl | Tramadol Hcl | 501 | 94 |
| Amlodipine Besylate | Amlodipine Besylate | 492 | 142 |
| Potassium Chloride | Potassium Chloride | 484 | 112 |
| Oxycodone Hcl | Oxycodone Hcl | 447 | 69 |
| Furosemide | Furosemide | 413 | 106 |
| Alprazolam | Alprazolam | 391 | 50 |
| Lisinopril | Lisinopril | 385 | 119 |
| Omeprazole | Omeprazole | 383 | 89 |
| Clonazepam | Clonazepam | 376 | 63 |
| Pregabalin | Pregabalin | 369 | 61 |
| Donepezil Hcl | Donepezil Hcl | 348 | 49 |
| Pantoprazole Sodium | Pantoprazole Sodium | 347 | 84 |
| Buspirone Hcl | Buspirone Hcl | 337 | 71 |
| Carvedilol | Carvedilol | 317 | 80 |
| Sertraline Hcl | Sertraline Hcl | 314 | 55 |
| Famotidine | Famotidine | 300 | 72 |
| Memantine Hcl | Memantine Hcl | 249 | 41 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 246 | 41 |
| Losartan Potassium | Losartan Potassium | 244 | 64 |
| Mirtazapine | Mirtazapine | 242 | 42 |
| Pravastatin Sodium | Pravastatin Sodium | 240 | 60 |
| Tamsulosin Hcl | Tamsulosin Hcl | 237 | 59 |
| Eliquis | Apixaban | 225 | 55 |
| Metformin Hcl | Metformin Hcl | 224 | 67 |
| Quetiapine Fumarate | Quetiapine Fumarate | 219 | 40 |
| Trazodone Hcl | Trazodone Hcl | 219 | 47 |
| Metoprolol Succinate | Metoprolol Succinate | 188 | 63 |
| Zolpidem Tartrate | Zolpidem Tartrate | 185 | 35 |
| Lorazepam | Lorazepam | 182 | 43 |
| Divalproex Sodium | Divalproex Sodium | 180 | 22 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 176 | 135 |
| Diazepam | Diazepam | 172 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 162 | 39 |
| Citalopram Hbr | Citalopram Hydrobromide | 160 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 158 | 51 |
| Jardiance | Empagliflozin | 149 | 52 |
| Tizanidine Hcl | Tizanidine Hcl | 146 | 51 |
| Fluticasone Propionate | Fluticasone Propionate | 144 | 50 |
| Escitalopram Oxalate | Escitalopram Oxalate | 141 | 28 |
| Methadone Hcl | Methadone Hcl | 140 | 15 |
| Bumetanide | Bumetanide | 133 | 34 |
| Spironolactone | Spironolactone | 133 | 33 |
| Trulicity | Dulaglutide | 132 | 23 |
| Meloxicam | Meloxicam | 127 | 33 |
| Baclofen | Baclofen | 126 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 122 | 40 |
| Duloxetine Hcl | Duloxetine Hcl | 112 | 30 |
| Promethazine Hcl | Promethazine Hcl | 110 | 30 |
| Valsartan | Valsartan | 109 | 37 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 105 | 26 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 102 | 26 |
| Montelukast Sodium | Montelukast Sodium | 102 | 29 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 101 | 15 |
| Finasteride | Finasteride | 97 | 19 |
| Xarelto | Rivaroxaban | 91 | 19 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 90 | 90 |
| Ozempic | Semaglutide | 90 | 30 |
| Simvastatin | Simvastatin | 90 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 88 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 88 | 28 |
| Ropinirole Hcl | Ropinirole Hcl | 87 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 85 | 21 |
| Alendronate Sodium | Alendronate Sodium | 84 | 14 |
| Nystatin | Nystatin | 81 | 50 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 80 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 75 | 30 |
| Ondansetron Odt | Ondansetron | 72 | 46 |
| Amitriptyline Hcl | Amitriptyline Hcl | 71 | 25 |
| Mounjaro | Tirzepatide | 71 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 70 | 22 |
| Olanzapine | Olanzapine | 70 | 11 |
| Memantine Hcl Er | Memantine Hcl | 68 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 66 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 66 | 21 |
| Fluconazole | Fluconazole | 65 | 24 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 65 | 16 |
| Bupropion Xl | Bupropion Hcl | 64 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 64 | 24 |
| Chlorthalidone | Chlorthalidone | 63 | 24 |
| Lamotrigine | Lamotrigine | 63 | 17 |
| Latanoprost | Latanoprost | 63 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 63 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 61 | 17 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 60 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 59 | 33 |
| Celecoxib | Celecoxib | 58 | 24 |
| Allopurinol | Allopurinol | 57 | 18 |
| Linzess | Linaclotide | 57 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 57 | 25 |
| Paroxetine Hcl | Paroxetine Hcl | 57 | 13 |
| Klor-Con M20 | Potassium Chloride | 56 | 28 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 55 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 55 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 55 | 14 |
| Metformin Hcl Er | Metformin Hcl | 54 | 13 |
| Risperidone | Risperidone | 54 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 53 | suppressed |
| Levetiracetam | Levetiracetam | 52 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 51 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 50 | 43 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 50 | 15 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 50 | 15 |
| Amiodarone Hcl | Amiodarone Hcl | 47 | 18 |
| Lovastatin | Lovastatin | 46 | 12 |
| Sucralfate | Sucralfate | 45 | 13 |
| Valacyclovir | Valacyclovir Hcl | 45 | 17 |
| Lidocaine | Lidocaine | 44 | suppressed |
| Glipizide Er | Glipizide | 42 | 12 |
| Entresto | Sacubitril/Valsartan | 41 | 19 |
| Azithromycin | Azithromycin | 40 | 29 |
| Cephalexin | Cephalexin | 39 | 19 |
| Aripiprazole | Aripiprazole | 38 | suppressed |
| Spravato | Esketamine Hcl | 38 | suppressed |
| Januvia | Sitagliptin Phosphate | 37 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 37 | suppressed |
| Prolastin C | Alpha-1-Proteinase Inhibitor | 37 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 37 | 28 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 36 | suppressed |
| Mupirocin | Mupirocin | 36 | 31 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 35 | suppressed |
| Levofloxacin | Levofloxacin | 35 | 28 |
| Clonidine Hcl | Clonidine Hcl | 34 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 34 | 16 |
| Prednisone | Prednisone | 34 | suppressed |
| Topiramate | Topiramate | 34 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 33 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 33 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 33 | suppressed |
| Rivastigmine | Rivastigmine | 33 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 33 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 32 | 11 |
| Estradiol | Estradiol | 32 | suppressed |
| Ibuprofen | Ibuprofen | 32 | 11 |
| Methocarbamol | Methocarbamol | 32 | 12 |
| Megestrol Acetate | Megestrol Acetate | 31 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 31 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 24 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 29 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 29 | suppressed |
| Amoxicillin | Amoxicillin | 28 | 22 |
| Bupropion Hcl Sr | Bupropion Hcl | 28 | suppressed |
| Fenofibrate | Fenofibrate | 27 | suppressed |
| Naproxen | Naproxen | 27 | suppressed |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 27 | suppressed |
| Colchicine | Colchicine | 26 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 26 | suppressed |
| Dexamethasone | Dexamethasone | 25 | 22 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 25 | 18 |
| Cholestyramine | Cholestyramine (With Sugar) | 24 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 24 | suppressed |
| Methotrexate | Methotrexate Sodium | 24 | suppressed |
| Phenobarbital | Phenobarbital | 24 | suppressed |
| Temazepam | Temazepam | 24 | suppressed |
| Timolol Maleate | Timolol Maleate | 24 | suppressed |
| Fentanyl | Fentanyl | 23 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 23 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Loperamide | Loperamide Hcl | 22 | 12 |
| Atenolol | Atenolol | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Enulose | Lactulose | 21 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 21 | suppressed |
| Mesalamine Dr | Mesalamine | 20 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 19 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Modafinil | Modafinil | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | 15 |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 18 | 18 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 18 | suppressed |
| Gemfibrozil | Gemfibrozil | 18 | suppressed |
| Gemtesa | Vibegron | 18 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 18 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 17 | suppressed |
| Kerendia | Finerenone | 17 | suppressed |
| Sodium Chloride | Sodium Chloride Irrig Solution | 17 | 11 |
| Vraylar | Cariprazine Hcl | 17 | suppressed |
| Belsomra | Suvorexant | 16 | suppressed |
| Carisoprodol | Carisoprodol | 16 | suppressed |
| Cefdinir | Cefdinir | 16 | 15 |
| Erythromycin | Erythromycin Base | 16 | 14 |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Ingrezza | Valbenazine Tosylate | 16 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 15 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | 14 |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Brinzolamide | Brinzolamide | 14 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 14 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Vascepa | Icosapent Ethyl | 14 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | 11 |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Nystop | Nystatin | 13 | suppressed |
| Roflumilast | Roflumilast | 13 | suppressed |
| Salsalate | Salsalate | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Xifaxan | Rifaximin | 13 | suppressed |
| Clobazam | Clobazam | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Dextroamphetamine Sulfate | Dextroamphetamine Sulfate | 12 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 12 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 12 | suppressed |
| Humalog | Insulin Lispro | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 12 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 12 | 12 |
| Neupro | Rotigotine | 12 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 12 | suppressed |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Risperdal Consta | Risperidone Microspheres | 12 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 12 | suppressed |
| Trimethoprim | Trimethoprim | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Butorphanol Tartrate | Butorphanol Tartrate | 11 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 11 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 11 | 11 |
| Rocklatan | Netarsudil Mesylat/Latanoprost | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
| Viberzi | Eluxadoline | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $688.29 · 48 records | ABBVIE INC. | ABRYSVO, BIOFIRE SPOTFIRE Control Station, Bylvay, CAPLYTA, COMIRNATY, ELIQUIS, FREESTYLE LIBRE 3, GLASSIA, JARDIANCE, Kerendia, Korlym, MAVYRET, NURTEC ODT, Ohtuvayre, PREVNAR 20, Prolastin-C Liquid, QULIPTA, REXULTI, SUBLOCADE, TZIELD, UBRELVY, UPLIZNA, VRAYLAR, XIFAXAN, ZAVZPRET | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error